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Abstract
Patients treated with curative-intent lung radiotherapy are in the group at highest risk of severe complications and death from COVID-19. There is therefore an
urgent need to reduce the risks associated with multiple hospital visits and their anti-cancer treatment. One recommendation is to consider alternative dose-
fractionation schedules or radiotherapy techniques. This would also increase radiotherapy service capacity for operable patients with stage I-III lung cancer, who
might be unable to have surgery during the pandemic.
Here we identify reduced-fractionation for curative-intent radiotherapy regimes in lung cancer, from a literature search carried out between 20/03/2020 and 30/
03/2020 as well as published and unpublished audits of hypofractionated regimes from UK centres. Evidence, practical considerations and limitations are
discussed for early-stage NSCLC, stage III NSCLC, early-stage and locally advanced SCLC. We recommend discussion of this guidance document with other
specialist lung MDT members to disseminate the potential changes to radiotherapy practices that could be made to reduce pressure on other departments such
as thoracic surgery. It is also a crucial part of the consent process to ensure that the risks and benefits of undergoing cancer treatment during the COVID-19
pandemic and the uncertainties surrounding toxicity from reduced fractionation have been adequately discussed with patients. Furthermore, centres shouldAuthor for correspondence: C. Faivre-Finn, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
E-mail address: Corinne.Finn@christie.nhs.uk (C. Faivre-Finn).
https://doi.org/10.1016/j.clon.2020.05.001
0936-6555/ 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C. Faivre-Finn et al. / Clinical Oncology 32 (2020) 481e489482document all deviations from standard protocols, and we urge all colleagues, where possible, to join national/international data collection initiatives (such as
COVID-RT Lung) aimed at recording the impact of the COVID-19 pandemic on lung cancer treatment and outcomes.
 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization declared COVID-19, the
disease caused by the 2019 novel coronavirus SARS-CoV-2, a
pandemic on 11 March 2020. This situation is resulting in
unprecedented demands on the National Health Service as a
whole, posing a major burden on cancer services in the UK.
About 49 000 new patients are diagnosed with lung
cancer each year in the UK and >50% require radiotherapy
treatment. The lung cancer population requiring active
treatment has been classified as ‘extremely vulnerable’,
with a significant proportion of previously treated lung
cancer patients included in this category due to coexisting
severe comorbidities [1,2]. There is, therefore, a need to
mitigate the risks of their anti-cancer treatments by
addressing risks associated with multiple visits to hospital,
treatment-induced immune suppression and radiation-
associated lung injury. This means adapting our current
treatment protocols rapidly to reflect the shifting
riskebenefit ratio and diminished resources. Furthermore,
the impact of this pandemic will probably last for a signif-
icant length of time beyond the resumption of normal ser-
vices. This is due to the anticipated backlog of patients
diagnosed with lung cancer and the increased demands on
the radiotherapy departments due to the deferral of radio-
therapy for disease sites such as breast and prostate.
General guidance on the delivery of radiotherapy during
the COVID-19 pandemic has been provided by the National
Institute for Health and Care Excellence [3]. One recom-
mendation is to consider alternative dose-fractionation
schedules or radiotherapy techniques.
The objectives of this article are: to identify reduced-
fractionation and curative-intent radiotherapy regimens in
lung cancer, assess their evidence base and provide organ at
risk (OAR) dose constraints. We also discuss limitations and
practical considerations associated with the implementation
of these reduced-fractionation regimens. The anticipated
impact of this work is first, to reduce hospital visits and limit
exposure to COVID-19 in patients having curative-intent
radiotherapy for lung cancer and, second, to increase radio-
therapy service capacity for operable patients with stage IeIII
lung cancer, who may not be able to have surgery during the
pandemic.
Methods
Systematic reviews and relevant papers were identified
by a group of UK clinical oncologists through a PubMed
search between 20 and 30 March 2020. We also included
published and unpublished audits of hypofractionated
regimens from UK centres.Early Stage Non-small Cell Lung Cancer
UK practice is based on the recommendations from the
UK stereotactic ablative radiotherapy (SABR) consortium
[4]. Here we outline the evidence for a reduction in SABR
fraction number and provide OAR dose constraints from
existing international protocols. We also outline the evi-
dence for hypofractionation (beyond 55 Gy in 20 fractions)
for central/ultra-central early stage non-small cell lung
cancer (NSCLC) not suitable for SABR due to OAR constraints
being exceeded.Single-Fraction Stereotactic Ablative Radiotherapy
Advice
 Consider 30e34 Gy in a single fraction in patients
with tumours that are 2 cm, >1 cm from the chest
wall and are outside of the no-fly zone. This is in
keeping with the current National Comprehensive
Cancer Network (NCCN) guidelines [5].Evidence
Single-fraction schedules of 30e34 Gy have been
compared with multi-fraction SABR in two phase II studies
(RTOG 0915, Roswell Park) [6e8]. Local control rate,
progression-free survival (PFS) and overall survival, as well
as late toxicity and quality of life, were comparable be-
tween single-fraction and multi-fraction SABR regimens.
Chest wall toxicity did not exceed grade 2 in either arm of
both studies. A retrospective study including 146 lesions
showed that grade 2e4 chest wall toxicity was 30.6% for
lesions abutting the chest wall, 8.2% for tumours 1 cm
from the chest wall and 3.8% for tumours 1e2 cm from the
chest wall [9]. Overall grade 3 chest wall toxicity was
1.4%.
Limitations
 A range of SABR dose/fractionation schedules have
been described, but no single regimen has been
established as the standard of care.
 Evidence is based on phase II data only, where the
numbers treated within 2 cm of the chest wall are
very small.
Practical considerations
 Only centres with prior experience of delivering lung
SABR should offer single-fraction SABR.
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those typically treated with 54 Gy in three fractions,
rather than 55 Gy in five fractions.
 It is advised only to consider tumours that move less
than 1 cm after appropriate motion management on
four-dimensional computed tomography imaging.
 The dose constraints recommended are those set out
in the RTOG 0915 study (see supplementary Tables
S1 and S2).
Stereotactic Ablative Radiotherapy for Tumours within 2.5
cm of the Chest Wall
Advice
 Consider three-fraction regimens (e.g. 54 Gy/three
fractions).
 Where the planning target volume (PTV) abuts or
overlaps the chest wall, consider 54 Gy/three frac-
tions or a reduced dose to minimise toxicity (e.g. 48
Gy/three fractions).Evidence
The rate of grade 3 chest wall toxicity with SABR from a
large meta-analysis (combining several different dose and
fractionations) is 1.2% [10]. Individual papers have found
that the tumour to chest wall distance is a significant factor,
as well as the maximum dose (Dmax) and the volume of
chest wall receiving 30 Gy (V30) [11e14]. Multi-fraction
retrospective data specifically looking at patients with tu-
mours near the chest wall are shown in supplementary
Table S3. Where the gross tumour volume is within 2.5
cm of the chest wall, no increased risk is seen with three
fractions compared with five fractions (1.6% compared with
3.2%, respectively) [13]. Where the PTV is abutting the chest
wall, data from Andolino et al. [11] suggest that 48 Gy/three
fractions has a lower toxicity than 54 Gy/three fractions.
Limitations
 The effect of fractionation schedules on chest wall
toxicity has not been investigated inprospective trials.Practical considerations
 Suggested chest wall dose constraints for three-
fraction schedules are D0.5cm3 < 60 Gy,
D5cm3< 40GyandV30< 30 cm3 (see supplementary
Tables S4.1 and S4.2).Stereotactic Ablative Radiotherapy for Moderately Central
Tumours
Advice
 Consider 50 Gy/five fractions in moderately central
tumours.Evidence
Moderately central early stage NSCLC is defined as a
lesion within 2 cm of the bronchial tree, trachea, major
vessels, oesophagus, heart, pericardium or brachial plexus,
or a PTV abutting mediastinal pleura or pericardium,
excluding ultra-central disease. An ultra-central lesion is
where the PTV abuts either the main bronchi or trachea.
Two fractionations are commonly used:
 four to five fractions as per American Society for
Radiation Oncology (ASTRO) guidelines (based
largely on studies using a total dose of 45e50 Gy)
[15].
 eight fractions as per the UK SABR consortium (total
dose 60 Gy) [4].
Retrospective studies show similar grade 3 or above
toxicity rates between 0 and 7.7% and local control rates
between 77.6 and 95%. There is a lack of prospective evi-
dence to suggest which regimen is superior. The safest arm
in the prospective RTOG 0813 trial was the 50 Gy/five
fractions cohort with no grade 3 toxic events. 50 Gy in five
fractions has been used in Glasgow based on the RTOG 0813
dose constraints [16]. In a study of 50 patients, there was a
4% grade 3 toxicity rate and a median overall survival of 27
months, which is consistent with other published literature
(see supplementary Table S5). 50 Gy in four fractions has
also been used in North America but lacks prospective trial
data and dose constraints.
Limitations
 There is no evidence to support one dose-
fractionation regimen being superior in terms of ef-
ficacy or safety.Practical considerations
 The dose constraints set out in RTOG 0813 are rec-
ommended (see supplementary Tables S6eS8).Stereotactic Ablative Radiotherapy for Tumours >5 cm
Advice
 Tumours >5 cm in diameter can be treated with
caution, provided that the OAR constraints for tu-
mours <5 cm can be met.Evidence
SABR is currently recommended for T1e2 tumours (or T3
tumours by virtue of invading chest wall) with a maximum
size of 5 cm [4]. Clinical trials have predominantly excluded
lesions larger than 5 cm and, therefore, conventional frac-
tionation schedules have been favoured in this group.
Woody et al. [17] reported on 40 patients with a median
tumour size of 5.6 cm (range 5.1e10 cm) treated with a
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control, overall survival and grade 3 toxicity rates were 91.2,
59.7 and 7.5%, respectively. A Dutch series reported on 63
patients with a median diameter of 5.8 cm (range 5.1e10.1)
with a longer median follow-up of 54.7 months [18]. The
median overall survival, 2-year local control and out-of-
field distant recurrence rates were 28.3 months, 95.8% and
10%, respectively. Thirty per cent developed grade 3
toxicity (radiation pneumonitis was the most common
toxicity) and 19% of deaths were treatment related.
Limitations
 There are no prospective data to support SABR for
tumours >5 cm.Practical considerations
 Dose constraints to OARs must be met as when
treating lesions 5 cm.
 Following treatment, patients should be closely
followed-up to detect and manage toxicity and ex-
pected higher distant relapse rates.Hypofractionation for Central/Ultra-central Early Stage
Tumours Not Suitable for Stereotactic Ablative Radiotherapy
Advice
 Consider 50e60 Gy in 15 fractions in patients with
central/ultra-central early stage NSCLC not suitable
for SABR based on OAR constraints.Evidence
A prospective phase I dose-escalation trial for patients of
performance status 2 with stage  II NSCLC not suitable
for surgery, SABR or chemoradiation used increasing doses
in 15 fractions (50 Gy, 55 Gy or 60 Gy) to validate OAR
constraints for a 15-fraction schedule in the intensity-
modulated radiotherapy (IMRT)/image-guided radio-
therapy era. They reported acceptable toxicities and no
dose-limiting toxicity was documented [19]. The subse-
quent randomised phase III study comparing 60 Gy in either
15 or 30 fractions in patients with performance status 2
stage IIeIII NSCLC has published interim results in abstract
form [20]. Sixty patients had been enrolled (88% stage III).
Chemotherapy was given to some patients sequentially
(before or after radiotherapy) but not concurrently. Less
toxicity was reported in the 15-fraction arm. Cho et al. [21]
retrospectively reviewed hypofractionated radiotherapy for
medically inoperable T1eT3 N0 NSCLC using a risk-adaptive
dose schedule (60 Gy in four, 15 or 20 fractions depending
on location, size and geometry of the tumour in relation to
the oesophagus). In total, 124 patients were included in the
study: 72.6% had T1e2 N0 tumours; 65.3% had centrally
located disease; 44.1% had performance status 2e3; and
20.2% received 60 Gy/15 fractions. In patients treated with15 fractions, the rate of grade 3 pneumonitis was 4%with no
grade 4e5 pneumonitis and no grade 2e5 oesophagitis
reported.
Limitations
 OAR constraints for 15-fraction schedules were
mostly derived from studies including patients with
performance status 2 and stage IIeIII disease.
 There are no prospective data to support 50e60 Gy in
15 fractions specifically in central or ultra-central
early stage NSCLC.Practical considerations
 Dose constraints to OARs for the 15-fraction schedule
must be met with particular attention to the oeso-
phageal constraint (see supplementary Table S9).Stage III Non-small Cell Lung Cancer
Concurrent Chemoradiotherapy
Advice
 Consider for selected patients (see practical consid-
erations below).
 Consider accelerated fractionation (i.e. 55 Gy/20
fractions).
 Limit chemotherapy dose (see practical consider-
ations below). Consider limiting chemotherapy to
two cycles only and starting radiotherapy with cycle
one.Evidence
The randomised phase II SOCCAR trial [22] compared
sequential versus concurrent chemotherapy combined with
55 Gy in 20 fractions. The median number of cycles deliv-
ered was 2.8 in the concurrent arm. Toxicity was similar
across both arms, with a median survival of 24 months
(concurrent arm) in a UK population of patients with stage
III NSCLC using three-dimensional planning and treatment
techniques. Following the study, a number of the partici-
pating centres adopted the schedule, fine-tuning chemo-
therapy regimens and evolving treatment techniques by
applying positron emission tomography-computed tomog-
raphy staging, four-dimensional planning, IMRT and volu-
metric modulated arc radiotherapy (VMAT). With these
adaptions, UK centres are reporting encouraging 58% 2-year
survival and acceptable rates of acute toxicity [23], which
compares favourably with more recent trials, e.g. PACIFIC
[24].
Limitations
The SOCCAR study only included 70 patients in the
concurrent arm. It was published before many of the more
modern staging and treatment techniques were in routine
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moradiotherapy using a hypofractionated accelerated frac-
tionation schedule is therefore limited (particularly
concerning acute and late toxicity) and of a retrospective
nature [23].
Practical Considerations
 The inclusion criteria for the SOCCAR study can guide
patient selection [22]. OAR constraints as per the
SOCCAR protocol are detailed in supplementary
Table S9.
 Chemotherapy as per the SOCCAR protocol [22] can
be adapted during the COVID-19 epidemic. Consid-
eration should be given to omitting the adjuvant
cycles and delivering the concurrent chemotherapy
cycles only (intravenous cisplatin 60 mg/m2 or car-
boplatin AUC5 day 1 and oral vinorelbine 40 mg/m2
days 1 and 8).Radical Radiotherapy  Sequential Chemotherapy
Advice
 Consider for selected patients (see practical consid-
erations below).
 Offer accelerated fractionation (55 Gy/20 fractions).
 Consider further hypofractionation (50e58 Gy in 15
fractions).
 If offered, limit chemotherapy to two cycles and
consider delivering it following radiotherapy (see
practical considerations below).Evidence
The hypofractionated regimen of 55 Gy/20 fractions has
been widely used in the UK [25], with audit data showing
similar outcomes to CHART, 99% of patients completing
treatment and a 7% grade 3 toxicity rate [26]. Retro-
spective data on 45 Gy in 15 fractions over 3 weeks (BED10
58.5 Gy) showed comparable outcomes to doses 60 Gy
given with conventional fractionation [27]. However,
radiobiological calculation suggests that this schedule
would not be isoeffective in comparison with 55 Gy/20
fractions (BED10 70.1 Gy). A higher dose hypofractionated
regimen of 60 Gy/15 fractions (BED10 90 Gy) has been re-
ported by Sunnybrook in patients with stage IeIII NSCLC
[28]. Forty-seven patients (52.8%) had stage IIeIII disease
and the 2-year survival was 68% for this group. Impor-
tantly, the dose constraints derived for this study corre-
spond well to those generated by Fenwick et al. [29] using
conversion from the I-START 20-fraction schedule (see
supplementary Table S9).
Limitations
Fifteen-fraction schedules have generally been used to
treat central early stage disease, with the treatment of stageIII patients limited to selected patients [28]. It should be
noted that the toxicity of this regimen has not been re-
ported specifically for patients with stage IIeIII.
Practical considerations
 Concerns over hypofractionated dose-escalated
radiotherapy in NSCLC are dominated by late radi-
ation toxicity involving central and perihilar
structures [30]. The experience of accelerated
schedules led to a UK research strategy that tested
four separate escalation protocols in phase I/II
studies. Two of these protocols used once daily
hypofractionated schedules (IDEAL-CRT, I-START)
with reassuring toxicity profiles [31,32]. Applying
the principles that Fenwick et al. [29] used to
develop these schedules to a 15-fraction schedule
delivered over 19e21 days:
o using an a/b of 10, 52 Gy/15 fractions is the
isoeffective dose for tumour control and using
an a/b of 3, 50 Gy/15 fractions is isotoxic to 55
Gy/20 fractions for late complications.
o 58 Gy/15 fractions would be the equivalent of
the highest dose cohorts in these two studies
(IDEAL-CRT 73 Gy/30 fractions over 6 weeks, I-
START 65 Gy/20 fractions over 4 weeks).
 The use of IMRT/VMAT is strongly recommended.
The radiotherapy planning guidelines for current
stage III studies [33] are a resource that can help
guide patient selection, outlining and planning using
the modified dose constraints in supplementary
Table S9.
 The addition of chemotherapy in the sequential
setting will need careful consideration, balancing a
4% absolute overall survival benefit over radio-
therapy alone [34] against the additional infective
risk posed by COVID-19. Consideration should be
given to radiotherapy first, with deferred chemo-
therapy given later when the risks related to COVID-
19 start decreasing.Small Cell Lung Cancer
Early Stage Small Cell Lung Cancer
Advice
 Consider SABR (with or without chemotherapy) in
T1-2 N0 M0 patients as an alternative to surgery or
fractionated radiotherapy. Dose/fractionation and
OAR constraints should be the same as those used for
early stage NSCLC.Evidence
SABR is standard of care in medically inoperable early
stage NSCLC and is increasingly being delivered for early
stage SCLC [35e38]. SABR for early stage SCLC is a treatment
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NCCN guidelines [40].
The largest series of SABR for limited stage SCLC is a
retrospective multicentre study including 74 patients [38],
of which only 59% of the patients received chemotherapy,
23% received prophylactic cranial irradiation (PCI) and
>30% of patients had an Eastern Cooperative Oncology
Group performance status 2e3. Toxicity wasmild, with 5.2%
grade 2 pneumonitis. Local PFS was 96.1% and overall
survival was 34% at 3 years.
Limitations
 Evidence base for SABR is limited to the peripheral
early stage SCLC setting. The risk of toxicity and
development of lymph node metastases for central/
ultra-central tumours is higher compared with pe-
ripheral tumours [41,42]. As data are lacking in ultra-
central early stage SCLC, conventionally fractionated
radiotherapy is more appropriate for these patients.
 Given the risk of distant metastases, chemotherapy is
generally considered in this setting for those patients
who are suitable [35,38].Practical considerations
 In the context of the COVID-19 pandemic, the
riskebenefit ratio of giving chemotherapy should be
considered carefully. In patients who are suitable for
chemotherapy, it is advisable to give SABR first as the
tumour volume may decrease significantly after the
first or second cycle of chemotherapy and become
difficult to visualise on image guidance.Radiotherapy Fractionation in Good Performance Status
Limited Stage Small Cell Lung Cancer Patients
Advice
 Consider 40 Gy in 15 daily fractions given with the
first or second cycle of chemotherapy in patients
with good performance status limited stage SCLC.
 Consider 40 Gy in 15 daily fractions after induction
chemotherapy in patients who are not suitable for
concurrent treatment.
 Limit chemotherapy to a maximum of four cycles.Evidence
The current standard of care is twice-daily radiotherapy
(45 Gy in 30 fractions) delivered concurrently with cycle 1
or 2 chemotherapy [43e45]. However, hypofractionated
regimens are also used in UK centres and include: 40 Gy in
15 fractions and 50e55 Gy in 20 fractions. A randomised
study by the National Cancer Institute of Canada showed a
survival benefit with early concurrent radiotherapy (week
1) versus late (week 15) using 40 Gy in 15 daily fractions
[46]. Toxicity in both arms was acceptable. Grade 4 neu-
tropenia was common and pneumonitis was<3%. Grønberget al. [47] reported a randomised phase II trial of 157 pa-
tients with limited stage SCLC treated with 42 Gy in 15
fractions once daily or 45 Gy in 30 fractions twice daily.
There was no difference in 1-year or median PFS. There
were no differences in grade 3 oesophagitis (once daily
31%, twice daily 33%, P ¼ 0.80) or pneumonitis (once daily
2%, twice daily 3%, P ¼ 1.0) [47]. Videtic et al. [48] retro-
spectively reviewed 122 limited stage SCLC patients who
received concurrent chemotherapy with 50 Gy in 25 frac-
tions over 5 weeks (92 patients) or 40 Gy in 15 fractions
over 3 weeks. There was no difference in treatment-related
toxicity, overall survival and thoracic local control. Xia et al.
[49] reported results on 59 limited stage SCLC patients
treated with 55 Gy in 22 fractions over 30 days and con-
current chemotherapy. Twenty-five per cent of patients
developed  grade 3 oesophagitis and 10% of patients
developed  grade 3 pneumonitis. 40 Gy in 15 fractions has
been used concurrently and sequentially in Leeds for
limited stage SCLC for >10 years. Institutional dose con-
straints are listed in supplementary Table S10 and a recent
unpublished audit of 43 limited stage SCLC patients treated
with concurrent chemoradiotherapy (40 Gy in 15 fractions)
showed a 1-year overall survival of 88% and a median
overall survival of 26.9 months (15.6e50.4).
Limitations
 The initial data on 40 Gy in 15 fractions are from 1993
[46] and, therefore, radiotherapy planning and de-
livery would be considered suboptimal.
 Most data on hypofractionated regimens are from
retrospective single-institution studies.
 A variety of different hypofractionated regimens are
used in the published literature and in routine UK
practice.Practical considerations
 When treating limited stage SCLC with hypofractio-
nated radiotherapy, intravenous contrast (if not
contraindicated) and three-dimensional computed
tomography/IMRT planning with an offline image-
guided radiotherapy protocol with volumetric im-
aging are considered the standard of care. Four-
dimensional computed tomography planning and
daily online cone-beam computed tomography
(CBCT) are highly recommended, particularly if OAR
doses are close to tolerance.
 Leeds’ OAR constraints for the 40 Gy/15 fractions
regimen are listed in supplementary Table S10.Discussion
This guidance document on reduced fractionation for
lung cancer being treated with curative intent during the
COVID-19 pandemic builds on a long tradition of hypo-
fractionated radiotherapy in the UK. It reflects the current
published literature and the combined experience of the
C. Faivre-Finn et al. / Clinical Oncology 32 (2020) 481e489 487authors and their colleagues in the UK and globally. How-
ever, it is acknowledged that for many centres, the frac-
tionation regimens outlined will represent a significant
change to current practice and standard of care. The extent
of adoption of this guidance may reflect geographical
pressures, although it is likely that all radiotherapy de-
partments will need to adapt during this global pandemic.
This guidance document should be discussed with other
specialist lung multidisciplinary team members, as access
to adequate nodal staging procedures (e.g. endobronchial
ultrasound-guided transbronchial needle aspiration [EBUS-
TBNA]) and respiratory function testing will probably be
compromised during the peak of the virus pandemic. That
discussion will disseminate the potential changes to radio-
therapy practice that could be made in order to alleviate
pressure on other departments, such as thoracic surgery.
Adequate discussionwith the patient about the risks and
benefits of treatment during the COVID-19 pandemic and
uncertainties about toxicity from reduced fractionation
where there is limited experience in a department are an
essential component of the consent process.
Centres should document deviations from standard pre-
treatment work-up as well as deviations from standard of
care treatments. We consider prospective and multi-centre
documentation of outcome (including toxicity) from these
reduced-fractionation regimens as essential. We also urge
colleagues to join national/international data collection
initiatives on the impact of the COVID-19 pandemic, such as
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